Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...

The condition, which most often affects people in warm, humid climates where fungal spores are common, can trigger nasal ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Eli Lilly expanded its AI drug discovery pact with XtalPi to antibodies. Celltrion in-licensed two innovative autoimmune ...

After spending much of the year sloping steadily downward from a January peak, TV drug ad spending picked up in a major way ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Akeso has data showing ivonescimab can extend the lives of patients with previously treated EGFR-mutated non-small cell lung ...

Incyte has expanded its support for projects tackling unmet needs to cover hidradenitis suppurativa (HS) patients, tightening ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

Less than three months into his tenure, Novo Nordisk’s new CEO has undeniably left his mark on the company, launching a ...

A proposed buyout of Bavarian Nordic by a private equity consortium didn’t win over enough shareholder support, laying to ...

As the prospect of import tariffs and drug price reform marshals billions of biopharma investment dollars into the U.S., the ...